Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

M. Brüggemann, M. Kotrová, H. Knecht, J. Bartram, M. Boudjogrha, V. Bystry, G. Fazio, E. Froňková, M. Giraud, A. Grioni, J. Hancock, D. Herrmann, C. Jiménez, A. Krejci, J. Moppett, T. Reigl, M. Salson, B. Scheijen, M. Schwarz, S. Songia, M....

. 2019 ; 33 (9) : 2241-2253. [pub] 20190626

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006213

Grant support
Wellcome Trust - United Kingdom
NV16-32568A MZ0 CEP Register
NV16-32568A MZ0 CEP Register

Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was spiked into each sample as a library-specific quality control and calibrator. NGS identified 259 (average 5.2/sample, range 0-14) clonal sequences vs. Sanger-sequencing 248 (average 5.0/sample, range 0-14). NGS primers covered possible IG/TR rearrangement types more completely compared with local multiplex PCR sets and enabled sequencing of bi-allelic rearrangements and weak PCR products. The cPT-QC showed high reproducibility across all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be used for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.

Bristol Genetics Laboratory Southmead Hospital Bristol UK

Central European Institute of Technology Masaryk University Brno Czech Republic

Centre for Cancer Research and Cell Biology Queen's University Belfast Belfast UK

Centro Ricerca Tettamanti University of Milano Bicocca Monza Italy

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University University Hospital Motol Prague Czech Republic

CNRS CRIStAL Université Lille Inria Lille France

Department of Hematology APHP Necker Enfants Malades and Paris Descartes University Paris France

Department of Hematology Hopital Pitié Salpêtrière Paris France

Department of Hematology University Hospital Schleswig Holstein Kiel Germany

Department of Hematology University Hospital Schleswig Holstein Kiel Germany Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Hematology University Hospital Schleswig Holstein Kiel Germany CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University University Hospital Motol Prague Czech Republic

Department of Immunohematology and Blood Transfusion Leiden University Medical Center Leiden The Netherlands

Department of Immunology Laboratory Medical Immunology Erasmus MC University Medical Center Rotterdam The Netherlands

Department of Paediatric Haematology Great Ormond Street Hospital London UK

Department of Pathology Radboud University Medical Center Nijmegen The Netherlands

Department of Pediatric Haematology Bristol Royal Hospital for Children Bristol UK

Hospital Universitario de Salamanca IBSAL Salamanca Spain

Insititute of Pathology Charité Universitätsmedizin Berlin Berlin Germany

Institute of Applied Biosciences Thessaloniki Greece

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006213
003      
CZ-PrNML
005      
20231114151423.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-019-0496-7 $2 doi
035    __
$a (PubMed)31243313
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Brüggemann, Monika $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.
245    10
$a Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study / $c M. Brüggemann, M. Kotrová, H. Knecht, J. Bartram, M. Boudjogrha, V. Bystry, G. Fazio, E. Froňková, M. Giraud, A. Grioni, J. Hancock, D. Herrmann, C. Jiménez, A. Krejci, J. Moppett, T. Reigl, M. Salson, B. Scheijen, M. Schwarz, S. Songia, M. Svaton, JJM. van Dongen, P. Villarese, S. Wakeman, G. Wright, G. Cazzaniga, F. Davi, R. García-Sanz, D. Gonzalez, PJTA. Groenen, M. Hummel, EA. Macintyre, K. Stamatopoulos, C. Pott, J. Trka, N. Darzentas, AW. Langerak, EuroClonality-NGS working group,
520    9_
$a Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was spiked into each sample as a library-specific quality control and calibrator. NGS identified 259 (average 5.2/sample, range 0-14) clonal sequences vs. Sanger-sequencing 248 (average 5.0/sample, range 0-14). NGS primers covered possible IG/TR rearrangement types more completely compared with local multiplex PCR sets and enabled sequencing of bi-allelic rearrangements and weak PCR products. The cPT-QC showed high reproducibility across all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be used for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.
650    _2
$a výpočetní biologie $x metody $7 D019295
650    _2
$a genová přestavba T-lymfocytů $x genetika $7 D015329
650    _2
$a geny pro imunoglobuliny $x genetika $7 D005803
650    _2
$a geny TcR $x genetika $7 D019672
650    _2
$a genetické markery $x genetika $7 D005819
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny $x genetika $7 D007136
650    _2
$a reziduální nádor $x genetika $7 D018365
650    _2
$a akutní lymfatická leukemie $x genetika $7 D054198
650    _2
$a receptory antigenů T-buněk $x genetika $7 D011948
650    _2
$a rekombinace genetická $x genetika $7 D011995
650    _2
$a referenční standardy $7 D012015
650    _2
$a reprodukovatelnost výsledků $7 D015203
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kotrová, Michaela $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany. CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Knecht, Henrik $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.
700    1_
$a Bartram, Jack $u Department of Paediatric Haematology, Great Ormond Street Hospital, London, UK.
700    1_
$a Boudjogrha, Myriam $u Department of Hematology, Hopital Pitié-Salpêtrière, Paris, France.
700    1_
$a Bystry, Vojtech $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Fazio, Grazia $u Centro Ricerca Tettamanti, University of Milano Bicocca, Monza, Italy.
700    1_
$a Froňková, Eva $u CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Giraud, Mathieu $u CNRS, CRIStAL, Université Lille, Inria Lille, France.
700    1_
$a Grioni, Andrea $u Centro Ricerca Tettamanti, University of Milano Bicocca, Monza, Italy.
700    1_
$a Hancock, Jeremy $u Bristol Genetics Laboratory, Southmead Hospital, Bristol, UK.
700    1_
$a Herrmann, Dietrich $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.
700    1_
$a Jiménez, Cristina $u Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
700    1_
$a Krejci, Adam $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Moppett, John $u Department of Pediatric Haematology, Bristol Royal Hospital for Children, Bristol, UK.
700    1_
$a Reigl, Tomas $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Salson, Mikael $u CNRS, CRIStAL, Université Lille, Inria Lille, France.
700    1_
$a Scheijen, Blanca $u Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Schwarz, Martin $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany. $7 xx0272090
700    1_
$a Songia, Simona $u Centro Ricerca Tettamanti, University of Milano Bicocca, Monza, Italy.
700    1_
$a Svaton, Michael $u CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
700    1_
$a van Dongen, Jacques J M $u Department of Immunohematology and Blood Transfusion (IHB), Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a Villarese, Patrick $u Department of Hematology, APHP Necker-Enfants Malades and Paris Descartes University, Paris, France.
700    1_
$a Wakeman, Stephanie $u Bristol Genetics Laboratory, Southmead Hospital, Bristol, UK.
700    1_
$a Wright, Gary $u Department of Paediatric Haematology, Great Ormond Street Hospital, London, UK.
700    1_
$a Cazzaniga, Giovanni $u Centro Ricerca Tettamanti, University of Milano Bicocca, Monza, Italy.
700    1_
$a Davi, Frédéric $u Department of Hematology, Hopital Pitié-Salpêtrière, Paris, France.
700    1_
$a García-Sanz, Ramón $u Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
700    1_
$a Gonzalez, David $u Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
700    1_
$a Groenen, Patricia J T A $u Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Hummel, Michael $u Insititute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Macintyre, Elizabeth A $u Department of Hematology, APHP Necker-Enfants Malades and Paris Descartes University, Paris, France.
700    1_
$a Stamatopoulos, Kostas $u Institute of Applied Biosciences, Thessaloniki, Greece.
700    1_
$a Pott, Christiane $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.
700    1_
$a Trka, Jan $u CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Darzentas, Nikos $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Langerak, A. W., $u Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. a.langerak@erasmusmc.nl. $d 1967- $7 xx0310084
710    2_
$a EuroClonality-NGS working group
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 33, č. 9 (2019), s. 2241-2253
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31243313 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20231114151420 $b ABA008
999    __
$a ok $b bmc $g 1525071 $s 1096269
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 33 $c 9 $d 2241-2253 $e 20190626 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
GRA    __
$p Wellcome Trust $2 United Kingdom
GRA    __
$a NV16-34272A $p MZ0 $a NV16-32568A $p MZ0
GRA    __
$a NV16-34272A $p MZ0 $a NV16-32568A $p MZ0
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options